NCT05752318

Brief Summary

The APRIL study aims at analyzing HIV reservoirs, latency and persistence on antiretroviral therapy. It enrolls HIV-infected adults providing blood samples of which peripheral blood mononuclear cells are stored. The frequency, phenotype and inducibility of HIV-infected cells are then analyzed. These parameters may vary across the different clinical and therapeutic settings.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
10mo left

Started Feb 2023

Longer than P75 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress80%
Feb 2023Feb 2027

First Submitted

Initial submission to the registry

January 12, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

February 27, 2023

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 2, 2023

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 25, 2027

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 25, 2027

Last Updated

March 2, 2023

Status Verified

January 1, 2023

Enrollment Period

3.9 years

First QC Date

January 12, 2023

Last Update Submit

February 28, 2023

Conditions

HIV Infected IndividualsInformed Consent

Keywords

HIVReservoirLatencyPersistence

Outcome Measures

Primary Outcomes (1)

  • HIV-Flow

    1 day

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

HIV-infected adults

You may qualify if:

  • HIV-infection
  • Adults (\>18 years)
  • Social insurance
  • Informed consent

You may not qualify if:

  • HIV-uninfected
  • \<18 years
  • Lack of social insurance
  • Lack or withdraw of consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITH DNA

Whole blood

Central Study Contacts

Pierre GANTNER, MCU-PH

CONTACT

03 69 55 16 32pierre.gantner@chru-strasbourg.fr

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 12, 2023

First Posted

March 2, 2023

Study Start

February 27, 2023

Primary Completion (Estimated)

January 25, 2027

Study Completion (Estimated)

February 25, 2027

Last Updated

March 2, 2023

Record last verified: 2023-01